Previous 10 | Next 10 |
2023-08-09 07:07:03 ET Charles River Laboratories press release ( NYSE: CRL ): Q2 Non-GAAP EPS of $2.69 beats by $0.05 . Revenue of $1.06B (+8.9% Y/Y) beats by $10M . The Company’s 2023 guidance for revenue growth and earnings per share is as follows ...
– Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) today r...
2023-08-08 14:24:20 ET Charles River Laboratories ( NYSE: CRL ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is $2.64 (-4.7% Y/Y) and the consensus Revenue Estimate is $1.05B (+7.9% Y/Y). Over the...
2023-08-02 11:31:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As a prolific cog in the economic machine, the healthcare industry has been a roller coaster ride over the past few years. With the global pandemic, economic slowdown and industry-wide disrup...
New CRADL spaces in Seattle and Philadelphia will provide flexible vivarium space for biopharmaceutical industry Charles River Laboratories International, Inc. (NYSE: CRL) announced the planned openings of Charles River Accelerator and Development Lab (CRADL®) locations in Seattle ...
2023-07-30 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-26 02:05:15 ET Summary Charles River Laboratories' share price has declined over 50% from its 2021 peak, presenting a potential buying opportunity for investors. The CRO company is facing headwinds from COVID's overhang and funding constraints amid higher interest rates. ...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 9 th , at 8:30 a.m. ET. Investors wi...
2023-07-13 12:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Although mega cap tech...
2023-07-02 12:00:52 ET The tables have turned for Contract services organizations (CROs), with their toplines under pressure amid a post-pandemic drop in demand for clinical trial services worsened by biotech’s funding woes. The group offers clinical trial management services for...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...